Galunisertib in combination with gemcitabine significantly improved the overall survival of patients with unresectable pancreatic cancer over gemcitabine monotherapy.37 NCB-0846 blocked TGFβ/SMAD signalling by downregulating TGFBRI gene expression. This evidence concerns the gene TGFB1 and pancreatic neoplasm.